Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Oncology Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.
The Oncology Market was valued at USD 320.3 billion in 2024, and is projected to reach USD 866.1 billion by 2034, rising at a CAGR of 10.8%.
The rising incidence of cancer worldwide remains the key driver of market expansion, prompting increased demand for advanced treatments and diagnostics. As cancer cases surge across all age groups, healthcare systems are intensifying efforts to improve patient outcomes through novel therapies, precision medicine, and technological advancements in diagnostics. The oncology sector continues to witness significant investment from pharmaceutical and biotechnology firms, leading to groundbreaking innovations in immunotherapies, targeted therapies, and early detection methods.
The growing focus on personalized medicine, driven by genomics and biomarker research, is transforming the landscape of cancer treatment. Government initiatives, rising healthcare expenditures, and increased awareness campaigns further contribute to market growth, emphasizing the urgent need for better accessibility to cutting-edge cancer therapies and diagnostics. 
The oncology market is categorized into two primary segments: cancer diagnostics and cancer treatment. The cancer treatment segment, valued at USD 174.8 billion in 2024, is anticipated to grow at a CAGR of 11.3% between 2025 and 2034. The expansion of this segment is attributed to an increasing number of cancer diagnoses and regulatory approvals for novel treatments. Recent breakthroughs, including CAR-T cell therapies and next-generation immunotherapies, are reshaping cancer care, offering patients enhanced survival rates and improved quality of life. As pharmaceutical companies accelerate research and development efforts, the pipeline for innovative oncology drugs continues to expand, providing new hope for patients battling various forms of cancer.
Oncology encompasses several cancer types, including lung, prostate, breast, and colorectal cancers. In 2024, the breast cancer segment accounted for USD 63.2 billion, securing a 20% market share. The rising prevalence of breast cancer, coupled with advancements in diagnostic imaging, liquid biopsies, and targeted therapies, fuels the segment's rapid growth. Increased awareness campaigns and enhanced screening programs are enabling early detection, significantly improving treatment success rates. The growing adoption of artificial intelligence in diagnostics and precision medicine in breast cancer treatment is also driving market expansion, paving the way for more effective, patient-centric therapeutic solutions.
U.S. Oncology Market is poised to reach USD 377.1 billion by 2034, positioning the country as a global leader in cancer research and treatment. The increasing cancer burden, combined with strong government support and robust investment from pharmaceutical and biotechnology companies, is accelerating innovation in the oncology sector. With a growing number of hospitals, research institutions, and healthcare providers focusing on developing next-generation diagnostic tools and therapies, the U.S. continues to spearhead advancements in cancer care.
The rising adoption of precision oncology, expansion of clinical trials, and continuous improvements in treatment accessibility further strengthen the market's trajectory, ensuring a steady demand for breakthrough cancer treatments and cutting-edge diagnostic technologies.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter's Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
The companies featured in this Oncology market report include:
- AbbVie
- Amgen
- AstraZeneca
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GE HealthCare Technologies
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co
- Novartis
- Pfizer
- F. Hoffmann-La Roche
- Sanofi
- Takeda Pharmaceutical Company Limited
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 135 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value (USD) in 2024 | $320.3 Billion |
| Forecasted Market Value (USD) by 2034 | $866.1 Billion |
| Compound Annual Growth Rate | 10.8% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
2.1 Industry 360 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising incidence of cancer globally
3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
3.2.1.3 Growing number of diagnostic laboratories in developing countries
3.2.1.4 Technological advancements in developed countries
3.2.2 Industry pitfalls and challenges
3.2.2.1 High capital investment coupled with high cost associated with diagnostic imaging system
3.2.2.2 High risk of side effects associated with cancer treatment and risks associated with CT scanners
3.2.2.3 Dearth of well-skilled and trained oncologists and radiologists
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Future market trends
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, by Cancer Diagnostics and Treatment, 2021-2034 ($ Mn)
5.1 Key trends
5.2 Cancer diagnostics
5.2.1 Tumor biomarkers test
5.2.2 Imaging
5.2.3 Biopsy
5.2.4 Liquid biopsy
5.2.5 Immunohistochemistry
5.2.6 In situ hybridization
5.3 Cancer treatment
5.3.1 Chemotherapy
5.3.2 Targeted therapy
5.3.3 Immunotherapy
5.3.4 Hormonal therapy
5.3.5 Other cancer treatments
Chapter 6 Market Estimates and Forecast, by Cancer Type, 2021-2034 ($ Mn)
6.1 Key trends
6.2 Lung cancer
6.3 Prostate cancer
6.4 Colon and rectal cancer
6.5 Gastric cancer
6.6 Esophageal cancer
6.7 Liver cancer
6.8 Breast cancer
6.9 Other cancer types
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Diagnostic imaging centers
7.5 Academia
7.6 Specialty clinics
7.7 Other end use
Chapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
9.1 AbbVie
9.2 Amgen
9.3 AstraZeneca
9.4 Bristol-Myers Squibb Company
9.5 Eli Lilly and Company
9.6 GE HealthCare Technologies
9.7 Gilead Sciences
9.8 GlaxoSmithKline
9.9 Johnson & Johnson
9.10 Merck & Co
9.11 Novartis
9.12 Pfizer
9.13 F. Hoffmann-La Roche
9.14 Sanofi
9.15 Takeda Pharmaceutical Company Limited
For more information about this report visit https://www.researchandmarkets.com/r/qw2trp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
